Coquitlam, Canada

Danny Leung

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 2001-2002

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Danny Leung in Pharmaceutical Compounds

Introduction

Danny Leung is a notable inventor based in Coquitlam, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with anti-proliferative activity. His work is essential in addressing various hyperproliferative disorders.

Latest Patents

Danny Leung holds 2 patents for his innovative work. His latest patents include "Antiproliferative 1,2,3-thiadiazole compounds" and "Pyrazole compounds." These pharmaceutical compositions are designed to promote apoptosis in cells that lack normal regulation of the cell cycle and death. The formulations of these compounds, when combined with a physiologically acceptable carrier, are useful in treating conditions such as tumor growth, lymphoproliferative diseases, and angiogenesis. The compounds are specifically substituted pyrazoles and pyrazolines.

Career Highlights

Danny Leung is currently associated with Kinetek Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His research focuses on developing effective treatments for serious health conditions, showcasing his commitment to improving patient outcomes.

Collaborations

Danny has collaborated with talented coworkers, including Zaihui Zhang and Jun Yan, to advance his research and development efforts. Their combined expertise contributes to the success of their projects.

Conclusion

Danny Leung's contributions to pharmaceutical innovations highlight his role as a key inventor in the field. His patents and ongoing work at Kinetek Pharmaceuticals, Inc. demonstrate his dedication to addressing critical health challenges through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…